The current global health threat by the novel coronavirus disease 2019 (COVID-19) requires
an urgent deployment of advanced therapeutic options available. The role of …

This article provides a broad spectrum about the nanoprodrug fabrication advances co‐
driven by prodrug and nanotechnology development to potentiate cancer treatment. The …

The long-acting antiretroviral cabotegravir and rilpivirine combination has just received FDA,
EMA and Health Canada approval. This novel drug delivery approach is about to …

The management of chronic conditions often requires patients to take daily medication for an
extended duration. However, the need for daily dosing can lead to nonadherence to the …

Long-acting formulations are designed to reduce dosing frequency and simplify dosing
schedules by providing an extended duration of action. One approach to obtain long-acting …

Self‐assembled prodrug nanoparticles with tumor‐responsive capacity have great potential
in tumor visualization and treatment. However, the nanoparticle formulas usually contain …

Introduction Poor or inconsistent adherence to daily oral pre-exposure prophylaxis (PrEP)
has emerged as a key barrier to effective HIV prevention. The advent of potent long-acting …

One of the main challenges in the development of long-acting injectables for HIV treatment
is the limited duration of drug release, which results in the need for frequent dosing and …

Ultra-long-acting integrase strand transfer inhibitors were created by screening a library of
monomeric and dimeric dolutegravir (DTG) prodrug nanoformulations. This led to an 18 …

The lymphatic system possesses the main viral replication sites in the body following viral
infection. Unfortunately, current antiretroviral agents penetrate the lymph nodes insufficiently …